SomaGenics Secures NIH Funding
News Oct 05, 2016
SomaGenics has been awarded a $1.8M two-year NIH SBIR Phase II grant to further develop its RealSeq–AC technology for next-generation sequencing (NGS) of small RNAs such as microRNA.
Real-Seq®-AC dramatically reduces bias in small RNA sequencing libraries compared to commercially available library construction methods. “Bias reduction is critical for the discovery of previously undetected RNAs and enables a more accurate analysis of small RNA abundances,” according to Dr. Sergei Kazakov, VP of Discovery Research at SomaGenics and Principal Investigator on the NIH grant.
This Phase II award allows SomaGenics to further develop the RealSeq-AC library construction approach including streamlining the workflow, increasing library yield, and broadening its utility beyond sequencing microRNAs to include other RNA species such tRNAs, fragments of mRNAs and long noncoding RNAs (lncRNAs).
“This additional funding will allow us to continue expanding and optimizing the RealSeq platform, further strengthening SomaGenics’ suite of tools for small RNA discovery and validation. Besides RealSeq, these tools also include our proprietary RT-qPCR technologies miR-ID and miR-Direct, which can be used to validate potential biomarkers discovered through sequencing”, commented Dr. Brian Johnston, CEO of SomaGenics.
Previous work by the International Multiple Sclerosis Genetics Consortium (IMSGC) has identified 233 genetic risk variants. However, these only account for about 20% of overall disease risk, with the remaining genetic culprits proving elusive. A new study has tracked down four of these hard-to-find genes.READ MORE
Scientists at McGill have found the answer to a question that perplexed Charles Darwin; if natural selection works at the level of the individual, fighting for survival and reproduction, how can a single colony produce worker ants that are so dramatically different in size – from “minor” workers to large-headed soldiers with huge mandibles – especially if they are sterile?
Scientists have developed a successful method to make truly personalized predictions of future disease outcomes for patients with certain types of chronic blood cancers. The study combined extensive genetic and clinical information to predict the prognosis for patients with myeloproliferative neoplasms.